Gene clusters-based pathway enrichment analysis identifies four pan-cancer subtypes with distinct molecular and clinical features

  • 0Biomedical Informatics Research Lab, School of Basic Medicine and Clinical Pharmacy, Pharmaceutical University, 211198, Nanjing, China.

|

|

Summary

This summary is machine-generated.

A new algorithm, PathClustNet, identifies four distinct cancer subtypes based on pathway activity. These subtypes show varied clinical and molecular features, paving the way for precision oncology treatments.

Area Of Science

  • Oncology
  • Bioinformatics
  • Computational Biology

Background

  • Tumor heterogeneity poses challenges in cancer research and treatment.
  • Existing pathway-based clustering methods require pre-defined pathways, limiting their scope.
  • Identifying distinct cancer subtypes is crucial for developing targeted therapies.

Purpose Of The Study

  • To develop and validate a novel algorithm, PathClustNet, for pathway-based cancer subtype identification.
  • To explore tumor heterogeneity using a data-driven approach without pre-specified pathways.
  • To uncover novel pan-cancer subtypes with distinct molecular and clinical characteristics.

Main Methods

  • Developed the PathClustNet algorithm for unsupervised pathway-based clustering.
  • Applied PathClustNet to The Cancer Genome Atlas (TCGA) pan-cancer dataset.
  • Identified gene clusters, associated overrepresented pathways, and calculated pathway enrichment scores for clustering.

Main Results

  • Identified four distinct pan-cancer subtypes (C1-C4) based on pathway enrichment.
  • Characterized subtypes by metabolic activity, immune/developmental/stromal activity, cell cycle/DNA repair activity, and neuronal pathway activity.
  • Subtypes exhibited differential TP53 mutation rates, tumor purity, genomic stability, and chemotherapy response.
  • Discovered correlations between clinical factors (age, smoking, infections, alcohol) and pathway activities.

Conclusions

  • PathClustNet provides a novel, unsupervised method for classifying pan-cancer subtypes.
  • The identified subtypes (C1-C4) represent distinct molecular and clinical entities.
  • These findings support the potential of pathway-based classification for advancing precision oncology.